The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Cellular and Molecular Life Sciences

• Publication date

  2019-01-25

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1007/s00018-019-03011-wPMID 30683985PMCID PMC11105223
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Health benefits of Mediterranean diet in nonalcoholic fatty liver disease

  2018cited by this paper
• Probiotic supplementation increases obesity with no detectable effects on liver fat or gut microbiota in obese Hispanic adolescents: a 16‐week, randomized, placebo‐controlled trial

  2018cited by this paper
• Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota

  2017cited by this paper
• Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents

  2017cited by this paper
• Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta‐omics‐based approach

  2017cited by this paper
• The impact of genetic polymorphisms on liver diseases: entering the era of personalized medicine.

  2017cited by this paper
• Protective Effect of Akkermansia muciniphila against Immune-Mediated Liver Injury in a Mouse Model

  2017cited by this paper
• Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.

  2017cited by this paper
• How nutrition and the maternal microbiota shape the neonatal immune system

  2017cited by this paper
• Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids[S]

  2017cited by this paper
• Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

  2016cited by this paper
• Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study

  2016cited by this paper
• Nonalcoholic Fatty Liver Disease in Latinos.

  2016cited by this paper
• Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism.

  2016cited by this paper
• The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota

  2016cited by this paper
• Choline metabolites: gene by diet interactions

  2016cited by this paper
• An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.

  2016cited by this paper
• Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease

  2016cited by this paper
• Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.

  2016cited by this paper
• Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease

  2016cited by this paper
• Impact of the gut microbiota on inflammation, obesity, and metabolic disease

  2016cited by this paper
• FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis

  2016cited by this paper
• Cross-talk between bile acids and intestinal microbiota in host metabolism and health

  2015cited by this paper
• Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease.

  2015cited by this paper
• Effects of synbiotic on anthropometry, lipid profile and oxidative stress in obese children.

  2015cited by this paper
• Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease.

  2015cited by this paper
• Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

  2015cited by this paper
• Role of the normal gut microbiota.

  2015cited by this paper
• Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease.

  2015cited by this paper
• Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability

  2015cited by this paper
• Gut microbiota and obesity

  2015cited by this paper
• Diet dominates host genotype in shaping the murine gut microbiota.

  2015cited by this paper
• Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice

  2015cited by this paper
• Patients Receiving Prebiotics and Probiotics Before Liver Transplantation Develop Fewer Infections Than Controls: A Systematic Review and Meta-Analysis.

  2015cited by this paper
• Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future.

  2015cited by this paper
• Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

  2015cited by this paper
• Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease.

  2015cited by this paper
• Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non‐alcoholic steatohepatitis

  2014cited by this paper
• Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice

  2014cited by this paper
• Compositional and functional features of the gastrointestinal microbiome and their effects on human health.

  2014cited by this paper
• Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study.

  2014cited by this paper
• Faecal Microbiota Composition in Adults Is Associated with the FUT2 Gene Determining the Secretor Status

  2014cited by this paper
• Choline supplementation protects against liver damage by normalizing cholesterol metabolism in Pemt/Ldlr knockout mice fed a high-fat diet.

  2014cited by this paper
• Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease.

  2014cited by this paper
• Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity.

  2014cited by this paper
• Combined effects of oligofructose and Bifidobacterium animalis on gut microbiota and glycemia in obese rats

  2014cited by this paper
• Influence of dietary fat on intestinal microbes, inflammation, barrier function and metabolic outcomes.

  2014cited by this paper
• A Model of Metabolic Syndrome and Related Diseases with Intestinal Endotoxemia in Rats Fed a High Fat and High Sucrose Diet

  2014cited by this paper
• The microbiota regulates susceptibility to Fas-mediated acute hepatic injury

  2014cited by this paper
• Lactobacillus rhamnosus GG Protects against Non-Alcoholic Fatty Liver Disease in Mice

  2014cited by this paper
• Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model.

  2013cited by this paper
• Metabolism of Cholesterol and Bile Acids by the Gut Microbiota

  2013cited by this paper
• Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH

  2013cited by this paper
• Fatty liver accompanies an increase in lactobacillus species in the hind gut of C57BL/6 mice fed a high-fat diet.

  2013cited by this paper
• Intestinal microbiota in patients with nonalcoholic fatty liver disease

  2013cited by this paper
• Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial

  2013cited by this paper
• Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease.

  2013cited by this paper
• Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study.

  2013cited by this paper
• Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways.

  2013cited by this paper
• Role of the intestinal microbiome in liver disease.

  2013cited by this paper
• Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.

  2013cited by this paper
• Dietary fructose in nonalcoholic fatty liver disease

  2013cited by this paper
• Molecular Characterization of the Fecal Microbiota in Patients with Nonalcoholic Steatohepatitis – A Longitudinal Study

  2013cited by this paper
• Therapeutic potential of fecal microbiota transplantation.

  2013cited by this paper
• Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula.

  2013cited by this paper
• Bifidobacterium CECT 7765 improves metabolic and immunological alterations associated with obesity in high‐fat diet‐fed mice

  2013cited by this paper
• A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-alcoholic fatty liver disease (NAFLD): a pilot study

  2013cited by this paper
• The effects of synbiotic supplementation on some cardio-metabolic risk factors in overweight and obese children: a randomized triple-masked controlled trial

  2013cited by this paper
• Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome.

  2012cited by this paper
• Bifidobacterium longum with Fructo-Oligosaccharides in Patients with Non Alcoholic Steatohepatitis

  2012cited by this paper
• The impact of the gut microbiota on human health: an integrative view.

  2012cited by this paper
• Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

  2012cited by this paper
• Structure, Function and Diversity of the Healthy Human Microbiome

  2012cited by this paper
• A metagenome-wide association study of gut microbiota in type 2 diabetes

  2012cited by this paper
• Effects of gut microbes on nutrient absorption and energy regulation.

  2012cited by this paper
• Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice

  2012cited by this paper
• Bacteroides uniformis CECT 7771 Ameliorates Metabolic and Immunological Dysfunction in Mice with High-Fat-Diet Induced Obesity

  2012cited by this paper
• Human gut microbiome viewed across age and geography

  2012cited by this paper
• Changes of Fecal Bifidobacterium Species in Adult Patients with Hepatitis B Virus-Induced Chronic Liver Disease

  2012cited by this paper
• Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice

  2012cited by this paper
• Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.

  2012cited by this paper
• Linkage of gut microbiome with cognition in hepatic encephalopathy.

  2012cited by this paper
• Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease.

  2012cited by this paper
• Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine.

  2012cited by this paper
• Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin-glucan fiber improves host metabolic alterations induced by high-fat diet in mice.

  2012cited by this paper
• Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity

  2012cited by this paper
• PATRIC: the Comprehensive Bacterial Bioinformatics Resource with a Focus on Human Pathogenic Species

  2011cited by this paper
• Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency.

  2011cited by this paper
• Assessment of the Fecal Lactobacilli Population in Patients with Hepatitis B Virus-Related Decompensated Cirrhosis and Hepatitis B Cirrhosis Treated with Liver Transplant

  2011cited by this paper
• Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice.

  2011cited by this paper
• Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial.

  2011cited by this paper
• Disease phenotype and genotype are associated with shifts in intestinal‐associated microbiota in inflammatory bowel diseases

  2011cited by this paper
• Intestinal Microbiota Was Assessed in Cirrhotic Patients with Hepatitis B Virus Infection

  2011cited by this paper
• Characterization of fecal microbial communities in patients with liver cirrhosis

  2011cited by this paper
• Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

  2011cited by this paper
• Genotype Is a Stronger Determinant than Sex of the Mouse Gut Microbiota

  2011cited by this paper
• Effects of Lactobacillus rhamnosus Strain GG in Pediatric Obesity-related Liver Disease

  2011cited by this paper
• Novel Evidence for Chronic Exposure to Endotoxin in Human Nonalcoholic Steatohepatitis

  2011cited by this paper
• Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice

  2010cited by this paper
• Pattern recognition receptors and inflammation.

  2010cited by this paper

• Paeoniflorin Alleviates Metabolic Dysfunction-Associated Steatotic Liver Disease by Inhibiting Hepatic Lipogenesis and Inflammation.

  2026cites this paper
• Multi-omics analysis of the gut-liver axis revealed the effects of different exercise interventions in NAFLD mice.

  2026cites this paper
• Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: A state-of-the-art review

  2026cites this paper
• Exploring the pathogenesis of NAFLD: a study of the correlation of gut microbes and metabolites in humanized mouse gut microbiota

  2026influential citation
• From Gasotransmitter to Therapeutic Insight: Unraveling the Role of H₂S in the Gut-Liver Axis during NAFLD.

  2026cites this paper
• Intestinal obstruction impairs the antitumor function of hepatic natural killer cells against colorectal cancer.

  2026cites this paper
• Metabolic factors associated with colorectal neoplasms: a single center retrospective cross-sectional analysis of colonoscopy patients.

  2026cites this paper
• FK506-binding protein-5 in high-fat diet-induced metabolic dysfunction-associated steatotic liver disease.

  2026cites this paper
• Analysis of the incidence and risk factors of colorectal polyps in patients with chronic hepatitis B complicated by non - alcoholic fatty liver disease

  2026cites this paper
• Gut–liver–muscle axis: linking gut microbiota dysbiosis to malnutrition and sarcopenia in liver disease

  2026cites this paper
• Metabolic dysfunction-associated fatty liver disease increases the risk of sleep abnormalities: an analysis of the National Health and Nutrition Examination Survey 2017-2020.

  2026cites this paper
• The Bidirectional Relationship Between Type 2 Diabetes and NAFLD/MASH: Pathophysiology, Screening Strategies, and Therapeutic Opportunities

  2026cites this paper
• Lycopene Attenuates T2 Mycotoxin-Induced Hepatotoxicity and Dysbiosis by Activating PPAR Signaling.

  2026cites this paper
• Nuclear Receptor-Targeted Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease

  2025cites this paper
• Research hotspots and trends in gut microbiota and nonalcoholic fatty liver disease: A bibliometric study

  2025cites this paper
• A Multi-Omics Study Reveals the Active Components and Therapeutic Mechanism of Erhuang Quzhi Formula for Non-Alcoholic Fatty Liver Disease

  2025cites this paper
• The association between the dietary index for gut microbiota and non-alcoholic fatty liver disease and liver fibrosis: evidence from NHANES 2017–2020

  2025cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes

  2025cites this paper
• Gut microbiota therapy in gastrointestinal diseases

  2025cites this paper
• Modulation of Gut Microbes and Hepatic Metabolites by PCP Ameliorates NASH and Fatigue-like Performance in Mice

  2025cites this paper
• Lactobacillus helveticus HY7804 Modulates the Gut–Liver Axis to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease in a Mouse Model

  2025cites this paper
• Protein hydrolysate from Atlantic salmon (Salmo salar) improves aging-associated neuroinflammation and cognitive decline in rats by reshaping the gut microbiota and Th17/Treg balance.

  2025cites this paper
• A Review of the Gut Microbiome and Its Role in Non-alcoholic Fatty Liver Disease

  2025cites this paper
• Altered Abundance of Butyrate‐Producing Lachnospiraceae by Maternal Diet During Pregnancy Potentially Influences MASLD‐Related Lipid Dysregulation in Male Rat Offspring

  2025cites this paper
• Gut microbiota as a metabolic mediator to prevent or attenuate MASLD

  2025cites this paper
• The Role of Short-Chain Fatty Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Diseases

  2025cites this paper
• Therapeutic Strategies to Modulate Gut Microbial Health: Approaches for Chronic Metabolic Disorder Management

  2025cites this paper
• Gut microbiota dysbiosis contributes to choline unavailability and NAFLD development

  2025cites this paper
• HIIT versus MICT in MASLD: mechanisms mediated by gut-liver axis crosstalk, mitochondrial dynamics remodeling, and adipokine signaling attenuation

  2025cites this paper
• Platelet‐derived apoptotic vesicles ameliorate nonalcoholic fatty liver disease by regulating lipid metabolism via apolipoprotein A‐II

  2025cites this paper
• Effect of the total flavonoids of Dracocephalum moldavica L. on metabolic associated fatty liver disease in rats

  2025cites this paper
• The ubiquitin–proteasome system: A potential target for the MASLD

  2025cites this paper
• Gut microbiota's role in NAFLD- and HBV/HCV-related hepatocellular carcinoma: Mechanisms and therapeutic implications.

  2025cites this paper
• Composition, Function, and Detection Methods of the Intestinal Barrier.

  2025cites this paper
• Gut Microbiota Dysbiosis and LPS/NLRP3/GSDMD Pyroptosis Drive Hepatic Fibrosis: Therapeutic Potential of a Synbiotic Intervention.

  2025cites this paper
• Mechanistic roles and intervention strategies involving gut microbiota, amino acid metabolism, and the tumor immune microenvironment in MAFLD-HCC progression

  2025cites this paper
• The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial

  2025cites this paper
• Synthetic biology strategies for engineering probiotics and commensal bacteria for diagnostics and therapeutics.

  2025cites this paper
• The Dual Role of Gut Microbiota and Their Metabolites in Hepatocellular Carcinoma: A Context-Dependent Framework

  2025cites this paper
• Taming fatty liver: can taurine combat metabolic dysfunction in MASLD?

  2025cites this paper
• Application of probiotic therapy in nonalcoholic fatty liver disease: mediating mechanism and future perspective

  2025cites this paper
• Liver regeneration in fatty liver disease: can metabolomics shed light on the contribution of the gut microbiome?

  2025cites this paper
• Polysaccharides from hawthorn fruit alleviate high-fat diet-induced NAFLD in mice by improving gut microbiota dysbiosis and hepatic metabolic disorder.

  2025cites this paper
• Association of daily sleep duration with risk of metabolic dysfunction-associated steatotic liver disease and adverse liver outcomes.

  2025cites this paper
• Bifidobacterium Adolescentis Prevent Diabetes Induced Liver Injury Via Pyroptosis Attenuation.

  2025cites this paper
• Polyethylene terephthalate microplastics affect gut microbiota distribution and intestinal damage in mice.

  2025cites this paper
• Gut microbiota modulation by Traditional Chinese Medicine: a translational strategy for metabolic dysfunction-associated steatotic liver disease

  2025cites this paper
• The liver-gut axis perspective: Exploring the pathogenesis of fatty liver.

  2025cites this paper
• The role of SIRT2 in homeostatic medicine and aging intervention

  2025cites this paper
• Current Research on Relevant Risk Factors Associated with Colorectal Polyp Development

  2025cites this paper
• Liver Sinusoidal Endothelium: The Hidden Interface in the Gut–Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease?

  2025cites this paper
• Efficacy of interventions with live combined Bacillus subtilis and Enterococcus faecium enteric-coated capsules in metabolic associated fatty liver disease patients: a meta-analysis of randomized controlled trials

  2025cites this paper
• The mechanisms and therapeutic potential of Atractylodes macrocephala Koidz in chronic liver disease management.

  2025cites this paper
• N6-Methyladenosine Modification in the Metabolic Dysfunction-Associated Steatotic Liver Disease

  2025cites this paper
• Regulation mechanism of Rosa roxburghii Tratt. (Cili) fruit vinegar on non-alcoholic fatty liver disease

  2025cites this paper
• Effects of dietary live microbes intake on a newly proposed classification system for steatotic liver disease

  2025cites this paper
• The interaction between various food components and intestinal microbiota improves human health through the gut-X axis: independently or synergistically.

  2025cites this paper
• Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity

  2025cites this paper
• The Role of Traditional Chinese Medicine in the Management of Nonalcoholic Fatty Liver Disease: Targeting Gut Microbiome.

  2025cites this paper
• Prevalence, risk factors, and metabolic implications of alcohol use disorders among male workers in Hebei Province, China: a cross-sectional study

  2025cites this paper
• Effect of synbiotics on the cardiovascular risk factors in patients with non-alcoholic fatty liver: a GRADE assessed systematic review and meta-analysis

  2025cites this paper
• Protective effects of Lactobacillus rhamnosus GG supernatant on metabolic associated fatty liver disease through intestinal barrier restoration and regulation of the regenerating gene 3γ

  2025cites this paper
• Role of gut microbiota dysbiosis in the pathogenesis of non-alcoholic fatty liver disease among obese individuals

  2025cites this paper
• Metabolomics for searching non-invasive biomarkers of metabolic dysfunction-associated steatotic liver disease in youth with vertical HIV

  2025cites this paper
• Regulatory Role and Biomarker Potential of Gut Microbiota Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease to Hepatocellular Carcinoma

  2025cites this paper
• MASLD Under the Microscope: How microRNAs and Microbiota Shape Hepatic Metabolic Disease Progression

  2025cites this paper
• Sodium alginate supplementation can alleviate non-alcoholic fatty liver disease in rats by restoring hepatic lipid metabolism and gut microbiota

  2025cites this paper
• Co-encapsulation of probiotics with functional components: design strategies, synergistic mechanisms, biomedical applications, and challenges for industrialization.

  2025cites this paper
• Food Minor Bioactive Compounds of Polyphenolic and Polyprenolic Nature Are Promising Agents for the Prevention and Therapy of Non-Alcoholic Fatty Liver Disease

  2025cites this paper
• Metabolic dysfunction-associated steatotic liver disease: epidemiological trends, risk factors, and the role of gut microbiota in disease progression (a literature review)

  2025cites this paper
• Genotypic and phenotypic characterization of Lacticaseibacillus paracasei HP-B1337 associated with lipotropic effect on high-fat-diet-induced obesity mice.

  2025cites this paper
• Pros and cons of different dietary patterns for the treatment of metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• Therapeutic Potential Targeting Gut Microbiota Modulation With Emphasis on Lactobacillus spp. in Common Metabolic Disorders: A Systematic Review

  2025cites this paper
• Aglycin ameliorates nonalcoholic fatty liver disease through modulation of the gut microbiota, restoration of the intestinal barrier, and inhibition of hepatic inflammation in mice.

  2025cites this paper
• Alleviation of taurine on lung injury in fatty liver hemorrhagic syndrome laying hens by improving antioxidant and anti-inflammatory capacity

  2025cites this paper
• Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review

  2024cites this paper
• Gut microbiome features and metabolites in non-alcoholic fatty liver disease among community-dwelling middle-aged and older adults

  2024cites this paper
• Dual-Stimuli-Responsive Gut Microbiota-Targeting Nitidine Chloride-CS/PT-NPs Improved Metabolic Status in NAFLD

  2024cites this paper
• Effects of plant natural products on metabolic-associated fatty liver disease and the underlying mechanisms: a narrative review with a focus on the modulation of the gut microbiota

  2024cites this paper
• Sex-Specific Associations Between Organophosphate Esters Metabolites and Metabolic Dysfunction-Associated Fatty Liver Disease in Chinese Adults

  2024cites this paper
• Effect of circadian rhythm change on gut microbiota and the development of nonalcoholic fatty liver disease in mice.

  2024cites this paper
• Novel insights into macrophage immunometabolism in nonalcoholic steatohepatitis.

  2024cites this paper
• Research progress, challenges and perspectives of phospholipids metabolism in the LXR-LPCAT3 signaling pathway and its relation to NAFLD (Review)

  2024cites this paper
• Metabolic Insights into Caffeine’s Anti-Adipogenic Effects: An Exploration through Intestinal Microbiota Modulation in Obesity

  2024cites this paper
• The relationship between folic acid and nonalcoholic fatty liver disease

  2024cites this paper
• Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation

  2024cites this paper
• Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications

  2024cites this paper
• Smilax China L. polysaccharide prevents HFD induced-NAFLD by regulating hepatic fat metabolism and gut microbiota.

  2024cites this paper
• Diagnostic performance of the GGT/HDL-C ratio for NAFLD in adults with obesity undergoing bariatric surgery.

  2024cites this paper
• Gut Microbiota Plays Essential Roles in Soyasaponin's Preventive Bioactivities against Steatohepatitis in the Methionine and Choline Deficient (MCD) Diet-Induced Non-Alcoholic Steatohepatitis (NASH) Mice.

  2024cites this paper
• Genome engineering of the human gut microbiome.

  2024cites this paper
• GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD.

  2024cites this paper
• Efficacy of Ganshuang granules on non-alcoholic fatty liver and underlying mechanism: a network pharmacology and experimental verification.

  2024cites this paper
• Probiotic yogurt regulates gut microbiota homeostasis and alleviates hepatic steatosis and liver injury induced by high‐fat diet in golden hamsters

  2024cites this paper
• Lipidomic analysis reveals alterations in hepatic FA profile associated with MASLD stage in patients with obesity.

  2024cites this paper
• Liver cirrhosis and complications from the perspective of dysbiosis

  2024cites this paper
• Common pathogenetic mechanisms of non-alcoholic fatty liver disease and polycystic ovary syndrome

  2024cites this paper
• Quantitative proteomics study of carnosine effect in an animal model of Western diet‐induced nonalcoholic fatty liver disease

  2024cites this paper
• Isomalt attenuates hepatic steatosis in rats via modulating gut microbiota and its metabolic function

  2024cites this paper
• Semaglutide alters gut microbiota and improves NAFLD in db/db mice.

  2024cites this paper